These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 19428302)

  • 1. Is complement good or bad for cancer patients? A new perspective on an old dilemma.
    Markiewski MM; Lambris JD
    Trends Immunol; 2009 Jun; 30(6):286-92. PubMed ID: 19428302
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer and the complement cascade.
    Rutkowski MJ; Sughrue ME; Kane AJ; Mills SA; Parsa AT
    Mol Cancer Res; 2010 Nov; 8(11):1453-65. PubMed ID: 20870736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complement as a Biological Tool to Control Tumor Growth.
    Macor P; Capolla S; Tedesco F
    Front Immunol; 2018; 9():2203. PubMed ID: 30319647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complement regulators and inhibitory proteins.
    Zipfel PF; Skerka C
    Nat Rev Immunol; 2009 Oct; 9(10):729-40. PubMed ID: 19730437
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune evasion by a staphylococcal complement inhibitor that acts on C3 convertases.
    Rooijakkers SH; Ruyken M; Roos A; Daha MR; Presanis JS; Sim RB; van Wamel WJ; van Kessel KP; van Strijp JA
    Nat Immunol; 2005 Sep; 6(9):920-7. PubMed ID: 16086019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression of complement regulatory proteins by adult human oligodendrocytes.
    Scolding NJ; Morgan BP; Compston DA
    J Neuroimmunol; 1998 Apr; 84(1):69-75. PubMed ID: 9600710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Staphylococcal complement inhibitors: biological functions, recognition of complement components, and potential therapeutic implications.
    Geisbrecht BV
    Adv Exp Med Biol; 2008; 632():221-36. PubMed ID: 19025125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of MLV vector particles from human complement.
    Breun S; Salmons B; Günzburg WH; Baumann JG
    Biochem Biophys Res Commun; 1999 Oct; 264(1):1-5. PubMed ID: 10527830
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complement in neurological disorders and emerging complement-targeted therapeutics.
    Dalakas MC; Alexopoulos H; Spaeth PJ
    Nat Rev Neurol; 2020 Nov; 16(11):601-617. PubMed ID: 33005040
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Progress in the knowledge of complement. II. Nephritic factors].
    Leibowitch J; Lesavre P
    Nouv Presse Med; 1979 Jul; 8(30):2447-8. PubMed ID: 493036
    [No Abstract]   [Full Text] [Related]  

  • 11. Recent developments in low molecular weight complement inhibitors.
    Qu H; Ricklin D; Lambris JD
    Mol Immunol; 2009 Dec; 47(2-3):185-95. PubMed ID: 19800693
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual role of complement in tumour growth and metastasis (Review).
    Stover C
    Int J Mol Med; 2010 Mar; 25(3):307-13. PubMed ID: 20127033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inactivation of complement by recombinant human C3 derivatives.
    Spillner F; Kölln J; Bredehorst R
    Adv Exp Med Biol; 2006; 586():347-60. PubMed ID: 16893083
    [No Abstract]   [Full Text] [Related]  

  • 14. Complement-mediated lysis of cultured osteosarcoma cell lines using chimeric mouse/human TP-1 IgG1 and IgG3 antibodies.
    Olafsen T; Munthe Lund CK; Bruland OS; Sandlie I; Michaelsen TE
    Cancer Immunol Immunother; 1999 Oct; 48(7):411-8. PubMed ID: 10501855
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The functional unity of the complement system and mononuclear phagocytes (author's transl)].
    Bitter-Suermann D
    Verh Dtsch Ges Pathol; 1980; 64():63-76. PubMed ID: 7013340
    [No Abstract]   [Full Text] [Related]  

  • 16. A tumor-expressed inhibitor of the early but not late complement lytic pathway enhances tumor growth in a rat model of human breast cancer.
    Caragine TA; Okada N; Frey AB; Tomlinson S
    Cancer Res; 2002 Feb; 62(4):1110-5. PubMed ID: 11861390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Unwelcome complement.
    Markiewski MM; Lambris JD
    Cancer Res; 2009 Aug; 69(16):6367-70. PubMed ID: 19654288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Complement in organ xenotransplantation].
    Dalmasso AP
    Rev Clin Esp; 1996 Mar; 196 Spec No():44-51. PubMed ID: 9206808
    [No Abstract]   [Full Text] [Related]  

  • 19. Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer.
    Rettig TA; Harbin JN; Harrington A; Dohmen L; Fleming SD
    Clin Immunol; 2015 Oct; 160(2):244-54. PubMed ID: 26145788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement inhibition in cancer therapy.
    Pio R; Ajona D; Lambris JD
    Semin Immunol; 2013 Feb; 25(1):54-64. PubMed ID: 23706991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.